Skip to main content

Table 3 Multivariate analysis of risk factors and HER-2/neu overexpression according to menopausal status

From: Correlation of breast cancer risk factors with HER-2/neu protein overexpression according to menopausal and estrogen receptor status

Risk Factors HER-2/neu+ Cases/controls OR (95% CI) HER-2/neu-Cases/controls OR (95% CI) Ratio of the OR's Cases+/cases- OR (95% CI)
PREMENOPAUSAL
Age at first full pregnancy(≥ 23 years) NS 3.56(1.70–7.46) NS
Body mass index(>29 kg/m2) NS 6.89(2.23–21.25) NS
Abortion or miscarriage(ever) NS 0.49(0.23–1.05) 3.12 (1.18–8.24)
First degree family history(positive) NS 3.30(1.10–9.96) 0.09 (0.01–0.85)
Use of oral contraceptives (ever) NS 11.19(3.7–33.84) 0.16 (0.04–0.60)
Age of menarche (≤ 12 years) 2.09 (0.99–4.42) NS NS
POSTMENOPAUSAL
Age at first full pregnancy(≥ 23 years) 2.19(1.23–3.91) 1.66(1.03–2.66) NS
Body mass index(>29 kg/m2) 4.83(2.75–8.49) 2.67(1.56–4.55) 2.23 (1.20–4.15)
Abortion or miscarriage(ever) 0.50(0.28–0.88) 0.62(0.39–0.97) NS
First degree family history(positive) NS 2.23(1.08–4.63) NS
Use of estrogens (ever) NS 10.70(2.71–42.31) 0.21 (0.04–1.08)
Use of oral contraceptives (ever) NS 6.47(1.89–22.16) NS
Age of menarche (≤ 12 years) NS 1.72(1.07–2.75) 0.54 (0.28–1.04)
ALL WOMEN
Age at first full pregnancy(≥ 23 years) 2.19(1.23–3.91) 1.66 (1.03–2.66) NS
Body mass index(>29 kg/m2) 4.83(2.75–8.49) 2.67(1.56–4.55) 2.23(1.20–4.15)
Abortion or miscarriage(ever) 0.50(0.28–0.88) 0.62(0.39–0.97) NS
First degree family history(positive) NS 2.23(1.08–4.63) NS
Use of estrogens (ever) NS 10.70(2.71–42.31) 0.21 (0.04–1.08)
Use of oral contraceptives (ever) NS 6.47(1.88–22.16) NS
Age of menarche (≤ 12 years) NS 1.72(1.07–2.75) 0.54 (0.28–1.04)
  1. Adjusted for age, residence, menopausal status, menopausal age, menarche age, use of OC, use of HRT, first degree family history, age at first full pregnancy, parity, abortion, lactation, medication to suppress lactation, radiation to the chest, body mass index and benign breast disease.
  2. NS: non significant.